Want to see HK:1846 full AI Analyst Report?
EuroEyes International Eye Clinic Limited (1846) AI Stock Analysis
EuroEyes International Eye Clinic Limited
(HKEX:1846)
The score is driven primarily by solid financial performance, especially revenue growth and resilient cash flow, which are the main strengths. Valuation is acceptable, but technical trends remain a drag because the stock trades below key moving averages and momentum is only neutral.
EuroEyes International Eye Clinic Limited (1846) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 702.02M
- Dividend Yield
- 2.00%
- Average Volume (3M)
- 22.97K
- Price to Earnings (P/E)
- 285.7
- Beta (1Y)
- 0.19
- Revenue Growth
- 20.54%
- EPS Growth
- -96.74%
- Country
- Hong Kong
- Employees
- 409
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
EuroEyes International Eye Clinic Limited Business Overview & Revenue Model
Company Description
EuroEyes International Eye Clinic Limited provides vision correction services in Germany, the People’s Republic of China, Denmark, and the United Kingdom. The company offers laser eye surgery in various options, including SMILE Pro, Femto-Lasik, PRK,...
How the Company Makes Money
EuroEyes primarily generates revenue by providing paid, patient-facing ophthalmology services through its clinics. Key revenue streams typically include: (1) procedure fees from elective vision correction treatments, where patients pay for surgical i...
EuroEyes International Eye Clinic Limited Financial Statement Overview
Summary
Strong revenue growth, positive cash generation, and manageable leverage support a solid score. Recent margin compression and a higher debt load temper the result, but overall financial health remains above average.
Income Statement
78PositiveBalance Sheet
82Very PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 873.25M | 796.04M | 715.68M | 714.29M | 610.29M | 632.93M |
| Gross Profit | 332.13M | 324.33M | 286.59M | 335.52M | 270.84M | 312.55M |
| EBITDA | 197.82M | 244.19M | 216.93M | 292.10M | 220.44M | 278.80M |
| Net Income | 2.49M | 54.45M | 82.28M | 131.24M | 89.47M | 133.56M |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.95B | 1.60B | 1.75B | 1.54B | 1.37B |
| Cash, Cash Equivalents and Short-Term Investments | 607.70M | 696.70M | 653.23M | 720.38M | 779.57M | 861.58M |
| Total Debt | 387.46M | 410.19M | 319.29M | 384.26M | 290.41M | 221.48M |
| Total Liabilities | 574.75M | 667.78M | 473.72M | 588.09M | 497.95M | 328.55M |
| Stockholders Equity | 1.22B | 1.25B | 1.09B | 1.13B | 1.01B | 1.01B |
Cash Flow | ||||||
| Free Cash Flow | 138.71M | 148.11M | 117.41M | 102.30M | 152.46M | 228.71M |
| Operating Cash Flow | 183.17M | 193.75M | 197.75M | 191.85M | 208.76M | 273.26M |
| Investing Cash Flow | -196.38M | -113.47M | -83.83M | -180.28M | -131.81M | -59.90M |
| Financing Cash Flow | -106.57M | -115.97M | -136.82M | -102.76M | -102.22M | -69.18M |
EuroEyes International Eye Clinic Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1846, the sentiment is Negative. The current price of 2.20 is below the 20-day moving average (MA) of 2.38, below the 50-day MA of 2.39, and below the 200-day MA of 2.61, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 34.04 is Neutral, neither overbought nor oversold. The STOCH value of 18.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1846.
EuroEyes International Eye Clinic Limited Peers Comparison
Overall Rating
HK:221973Outperform- HK:184669Neutral
HK:330966Neutral
HK:386954Neutral
HK:072242Neutral
HK:388641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2219 | 73Outperform | HKD 1.66B | 8.33 | 6.97% | 10.27% | 3.85% | -1.23% |
| HK:1846 | 69Neutral | HKD 703.50M | 285.71 | 0.20% | 2.00% | 20.54% | -96.74% |
| HK:3309 | 66Neutral | HKD 1.05B | 10.10 | 5.57% | 2.35% | 4.75% | ― |
| HK:3869 | 54Neutral | HKD 467.79M | -143.32 | -0.41% | ― | 3.16% | -101.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:0722 | 42Neutral | HKD 292.35M | -3.79 | -10.76% | 9.04% | -1.37% | -334.69% |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1846 | EuroEyes International Eye Clinic Limited | 2.20 | -1.05 | -32.37% | |
| HK:2219 | Chaoju Eye Care Holdings Ltd. | 2.35 | 0.05 | 2.00% | |
| HK:3309 | C-MER Eye Care Holdings Limited | 0.86 | -0.89 | -51.00% | |
| HK:3869 | Hospital Corporation of China Ltd | 3.28 | -2.71 | -45.24% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.15 | -0.12 | -43.01% | |
| HK:0722 | UMP Healthcare Holdings Limited | 0.38 | -0.07 | -15.35% |
EuroEyes International Eye Clinic Limited Corporate Events
EuroEyes Updates Board and Committee Structure Effective November 2026
EuroEyes International Eye Clinic Limited has announced the composition of its board of directors effective 1 November 2026, naming Dr. Jørn Slot Jørgensen as chairman among a slate of executive, non-executive, and independent non-executive...
EuroEyes Restructures Senior Leadership as CFO Bracklo Moves to Non-Executive Role
EuroEyes International Eye Clinic Limited has announced that Chief Financial Officer Marcus Huascar Bracklo will resign from his CFO role and cease to serve as the company’s authorised representative under Hong Kong listing rules, effective 31...
EuroEyes Sets Board and Committee Roles Effective End-October 2026
EuroEyes International Eye Clinic Limited has confirmed the composition of its board of directors effective 31 October 2026, comprising four executive directors and three independent non-executive directors, with Dr. Jørn Slot Jørgensen ser...
EuroEyes Publishes Unaudited Interim Results for First Half of 2026
EuroEyes International Eye Clinic Limited has released its unaudited interim results for the six months ended 30 June 2026, covering the consolidated financial position, comprehensive income, cash flows and equity changes of the Group. The full inter...
EuroEyes warns interim loss amid acquisition costs but underlying business stays firm
EuroEyes International Eye Clinic Limited has warned that it expects to post a loss of HK$10 million to HK$17 million for the six months ended 30 June 2026, reversing a profit of HK$38.4 million a year earlier. The board attributes the swing primaril...
EuroEyes Schedules Board Meeting to Approve 2026 Interim Results and Consider Dividend
EuroEyes International Eye Clinic Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026 and to consider the publication of those figures. The board will also evaluate...
EuroEyes Bolsters European Push with Appointment of New Executive Director
EuroEyes International Eye Clinic Limited has appointed 60-year-old Rens Laurentius Michaël Schoenmakers as an executive director effective 3 August 2026, strengthening its leadership bench with a veteran of the medical devices, medtech and heal...
EuroEyes clarifies board and committee roles in governance update
EuroEyes International Eye Clinic Limited has updated its board composition, confirming a slate of five executive directors and three independent non-executive directors effective 3 August 2026, with founder Dr. Jørn Slot Jørgensen serving...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026